•    Enable prediction of cancer cell affinity to liposomal nanoparticles
•    Applicable to multiple nanoparticle formulations
•    Enable identification of cancer patient cohorts likely to respond favorably to nanotherapeutics
•    Effective trafficking of liposomal nanoparticles to aggressive tumors with low SLC46A3 expression
•    Potentially expandable to disease indications beyond oncology 
•    Potentially applicable to additional kinds of nanoparticles